Slide 15 -
|
EGFR as a Target for NSCLC Standard of Care in 2012 Epidermal growth factor receptor (EGFR) inhibition in advanced NSCLC
10% response rate in advanced disease, 30% prolonged stabilization
Survival advantage (erlotinib)
Shepherd, F. A. et al. N Engl J Med 2005;353:123-132
Mutually exclusive with K-ras
Most benefit for non-smoking related NSCLC, with EGFR mutations (females, adenocarcinomas, Asian)
Lynch et al., NEJM 350:2129, 2004; Paez et al., Science 304:1497, 2004; Pao et al., PNAS 101:13306, 2004
Mechanisms of secondary resistance to EGFR inhibitors being identified (T790M mutation-50%, Met amplification-10-20%, others)
Pao et al., PLoS Med 2:e17, 2005; Engelman et al., Science 316:1039, 2007
Erlotinib approved as single agent for 2nd and 3rd line treatment of NSCLC
Also for maintenance after 1st line non-progression after chemo
|